Publications and presentations
Susana Banerjee, James Stewart, Nuria Porta, Christy Toms, Alexandra Leary, Stephanie Lheureux, Saira Khalique, Jeremy Tai, Ayoma Attygalle, Katherine Vroobel, Christopher J Lord, Rachael Natrajan, Judith Bliss. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI) Int J Gynecol Cancer 2021 Nov;31(11):1471-1475. Available at https://ijgc.bmj.com/content/31/11/1471
S. Banerjee, A. Leary, S. Lheureux, J. Stewart, A. Attygalle, K. Vroobel, S. Gill, Z. Ali, J. Tai, C. Toms, R. Natrajan, C.J. Lord, N. Porta, J. Bliss. 815TiP ENGOT/GYN1/NCRI: ATR inhibitor in combination with olaparib in gynaecological cancers with ARID1A loss or no loss (ATARI) Abstract only. Annals of Oncology 2021 Sept; 32(Supp. 5) S768. Available at: https://www.sciencedirect.com/science/article/pii/S0923753421034864?via%3Dihub#sec3
S. Banerjee, A. Leary, J.R. Stewart, M. Dewan, S. Lheureux, A.R. Clamp, I.L. Ray-Coquard, F. Selle, C. Gourley, R.M. Glasspool, R. Bowen, A. Attygalle, K. Vroobel, N. Tunariu, K. Wilkinson, C. Toms, R. Natrajan, J. Bliss, C. Lord, N. Porta. 34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1/NCRI ATARI trial. ESMO Open 2023 Feb, 8(1) Supp 1: 100814. Available at: https://www.esmoopen.com/article/S2059-7029(23)00034-0/fulltext